Techonology and Science20 October, 20252 min read
Joe Biden Completes Radiation Therapy for Aggressive Prostate Cancer
This article is an automated aggregation of coverage from news outlets. Our editorials offer in-depth analysis curated by the NewsCord team.
Joe Biden completed several weeks of radiation therapy for aggressive prostate cancer. Treatment occurred at Penn Medicine Radiation Oncology in Philadelphia.
9 outlets told this the same way.
Joe Biden's Cancer Treatment Update
Former President Joe Biden, 82, has completed radiation therapy for an aggressive, high-risk, metastasized prostate cancer. His treatment was provided at the University of Pennsylvania/Penn Medicine Radiation Oncology in Philadelphia. The completion of his therapy was marked by the customary bell-ringing at the clinic.
“Former President Joe Biden, 82, has completed a round of radiation therapy for an aggressive, high-risk form of metastasized prostate cancer at the University of Pennsylvania’s Radiation Oncology clinic.”
His daughter Ashley Biden highlighted the moment and praised him as “so brave.” Multiple outlets report that the diagnosis was first announced in May and that the cancer had spread to his bones.
Coverage consistently notes the high aggressiveness of the disease, with a Gleason score of 9. Reports also emphasize the visible support from his family during this phase of treatment.
Biden's Cancer Treatment Details
Reports differ modestly on the exact duration and composition of Biden’s treatment, but agree that radiation began in October and recently concluded in Philadelphia. Newsweek specifies a “five-week course” of radiation and notes that hormone therapy is ongoing. CBS News describes the radiation period as “several weeks” and emphasizes that completing this phase does not end the overall care.
The Guardian states that radiation started “earlier in October” and highlights the bell-ringing moment marking the end of this treatment phase. The outlet Букви adds that Biden “began a course of pills earlier this year and recently started radiotherapy,” indicating systemic therapy beyond radiation.
Biden's Cancer Diagnosis Details
Reports agree that Biden’s cancer is aggressive and advanced. Many sources mention a Gleason score of 9 and that the cancer has spread to the bones. CBS News and WKMG both state the disease has spread to his bones.
“His cancer was graded with a Gleason score of 9, indicating a highly aggressive form.”
Newsweek describes the cancer as metastasized. The Guardian calls it high-risk and metastasized.
SSBCrack highlights the high Gleason score and notes that symptoms followed urinary issues. Букви quotes Biden’s optimism that the cancer is in his bones but has not spread further.
Biden's Dermatologic Care and Schedule
Several sources report on related dermatologic procedures and President Biden’s ongoing public schedule. SSBCrack and WKMG mention that he recently had skin cancer lesions removed from his forehead. Newsweek and Букви state that he underwent Mohs surgeries to remove skin tumors or lesions.
Букви also notes his expected public appearances, including receiving a Lifetime Achievement Award in Boston and chairing a Democratic Party event in Nebraska. The same source expresses gratitude to Penn Medicine for their care. The Guardian highlights the presence of Biden’s family during his treatment, showing photos with Jill Biden and their grandchildren.
Cancer Treatment and Reporting
Outlook assessments vary but converge on caution. CBS News notes finishing radiation is a positive step yet does not mean his treatment is over, with ongoing monitoring. Newsweek says therapy includes ongoing hormone treatment and that experts note the cancer is hormone-sensitive, potentially improving outcomes.
“While finishing radiation is a positive sign, it does not mean his treatment is over, as doctors will continue to monitor his progress to determine if further treatment is needed.”
Букви relays Biden’s optimism that there has been no further spread. Notably, prevalence framing differs: CBS News calls prostate cancer the second most common cancer among men, while Newsweek calls it the most common cancer among U.S. men, reflecting inconsistent epidemiology framings across outlets. Several outlets also highlight appreciation for Penn Medicine’s staff during this period.
